PIRAMAL PHARMA LIMITED — Call Transcript 2026

Jan 30, 2026

==> picture [145 x 61] intentionally omitted <==

30[th] January, 2026

BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635

National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 NSE symbol: PPLPHARMA

Sub: Transcript of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31[st] December, 2025

Dear Sir / Madam,

In continuation of our letter dated 16[th] January, 2026 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Conference Call held on 29[th] January, 2026, on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31[st] December, 2025, is available on the Company’s website at https://www.piramalpharma.com/financial-reports.

Kindly take this on record.

Thanking you,

Yours truly,

For Piramal Pharma Limited

TANYA Digitally signed by TANYA SANISH Date: 2026.01.30 SANISH 17:48:42 +05'30'

Tanya Sanish Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592 Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T: +91 22 3802 3000 / 4000; Email : shareholders.ppl@piramal.com piramalpharma.com